See more : GENinCode plc (GENI.L) Income Statement Analysis – Financial Results
Complete financial analysis of Theriva Biologics, Inc. (TOVX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Theriva Biologics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Gowest Gold Ltd. (GWA.V) Income Statement Analysis – Financial Results
- Inission AB (publ) (INISS-B.ST) Income Statement Analysis – Financial Results
- UNITED, Inc. (2497.T) Income Statement Analysis – Financial Results
- Hunan Gold Corporation Limited (002155.SZ) Income Statement Analysis – Financial Results
- Roblox Corporation (RBLX) Income Statement Analysis – Financial Results
Theriva Biologics, Inc. (TOVX)
About Theriva Biologics, Inc.
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.16M | 103.09K | 0.00 | 0.00 | 0.00 | 0.00 | 10.00K | 874.10K | 506.57K | 399.38K | 400.00K | 500.00K | 500.00K | 100.00K | 100.00K | 100.00K |
| Cost of Revenue | 135.00K | 268.00K | 87.00K | 201.00K | 240.00K | 272.00K | 245.00K | 157.00K | 72.00K | 0.00 | 0.00 | 0.00 | 0.00 | 467.62K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 118.78K | 86.34K | 100.00K | 100.00K | 100.00K | 0.00 | 0.00 | 100.00K |
| Gross Profit | -135.00K | -268.00K | -87.00K | -201.00K | -240.00K | -272.00K | -245.00K | -157.00K | -72.00K | 0.00 | 0.00 | 0.00 | 0.00 | 2.70M | 103.09K | 0.00 | 0.00 | 0.00 | 0.00 | 10.00K | 874.10K | 387.80K | 313.04K | 300.00K | 400.00K | 400.00K | 100.00K | 100.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 85.22% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 76.55% | 78.38% | 75.00% | 80.00% | 80.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 14.31M | 11.72M | 7.80M | 5.13M | 11.08M | 11.84M | 18.78M | 29.11M | 32.91M | 14.49M | 6.51M | 12.29M | 3.34M | 1.58M | 1.20M | 4.64M | 6.33M | 2.67M | 946.07K | 3.62M | 6.00M | 3.75M | 3.42M | 2.40M | 5.40M | 0.00 | 4.40M | 0.00 | 0.00 |
| General & Administrative | 7.16M | 9.86M | 6.47M | 5.03M | 4.58M | 5.73M | 7.47M | 10.14M | 8.07M | 6.01M | 5.07M | 5.01K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 624.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 763.00K | 5.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.78M | 9.86M | 6.47M | 5.03M | 4.58M | 5.73M | 7.47M | 10.14M | 8.07M | 6.01M | 5.83M | 5.01M | 2.59M | 2.70M | 2.58M | 2.68M | 3.81M | 1.44M | 285.70K | 4.48M | 4.55M | 2.82M | 2.28M | 3.00M | 4.60M | 7.70M | 3.00M | 6.40M | 3.60M |
| Other Expenses | -660.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.43M | 21.58M | 14.27M | 10.16M | 15.66M | 17.57M | 26.25M | 39.25M | 40.98M | 20.50M | 12.34M | 17.30M | 5.93M | 4.28M | 3.78M | 7.32M | 10.14M | 4.10M | 1.32M | 8.26M | 10.68M | 6.68M | 5.79M | 5.50M | 10.10M | 7.80M | 7.40M | 6.40M | 3.70M |
| Cost & Expenses | 21.43M | 21.58M | 14.27M | 10.16M | 15.66M | 17.57M | 26.25M | 39.25M | 40.98M | 20.50M | 12.34M | 17.30M | 5.93M | 4.75M | 3.78M | 7.32M | 10.14M | 4.10M | 1.32M | 8.26M | 10.68M | 6.80M | 5.87M | 5.60M | 10.20M | 7.90M | 7.40M | 6.40M | 3.80M |
| Interest Income | 1.44M | 512.00K | 6.00K | 44.00K | 283.00K | 67.00K | 21.00K | 37.00K | 6.00K | 3.00K | 33.00K | 33.00K | 14.00K | 413.00 | 2.97K | 128.24K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.11K | 9.88K | 13.83K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 135.00K | 268.00K | 87.00K | 201.00K | 240.00K | 272.00K | 245.00K | 157.00K | 72.00K | 20.00K | 43.00K | 63.00K | 201.00K | 358.71K | 382.09K | 404.62K | 199.63K | 30.68K | 2.26K | -154.13K | -130.55K | -118.78K | -86.34K | -100.00K | -100.00K | -100.00K | 0.00 | 0.00 | -100.00K |
| EBITDA | -19.85M | -21.58M | -14.19M | -9.96M | -15.42M | -17.30M | -26.01M | -39.10M | -40.91M | -20.48M | -11.53M | -17.22M | -7.48M | -1.22M | -3.34M | -6.91M | -9.94M | -4.07M | -1.28M | -8.09M | -9.76M | -6.42M | -5.39M | -5.15M | -7.90M | -7.40M | -7.30M | -6.30M | -3.60M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -38.71% | -3,158.80% | 0.00% | 0.00% | 0.00% | 0.00% | -80,946.53% | -1,116.24% | -1,266.71% | 2,407.29% | 2,025.00% | -1,940.00% | -1,480.00% | -7,300.00% | -6,400.00% | -3,500.00% |
| Operating Income | -21.43M | -21.58M | -14.27M | -10.16M | -15.66M | -17.57M | -26.25M | -39.25M | -40.98M | -20.50M | -12.34M | -17.30M | -5.93M | -1.58M | -3.68M | -7.32M | -10.14M | -4.12M | -1.36M | -8.09M | -9.68M | -6.30M | 9.70M | 8.20M | -9.60M | -7.30M | -7.30M | -6.40M | -3.40M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -50.05% | -3,571.17% | 0.00% | 0.00% | 0.00% | 0.00% | -80,946.53% | -1,107.12% | -1,243.26% | 2,428.90% | 2,050.00% | -1,920.00% | -1,460.00% | -7,300.00% | -6,400.00% | -3,400.00% |
| Total Other Income/Expenses | 1.44M | 471.00K | 6.00K | 44.00K | 283.00K | 4.15M | 10.76M | 11.45M | -3.81M | 718.00K | 21.00K | 15.00K | -1.70M | -127.21K | -43.01K | -357.00 | 245.88K | -12.50K | 1.34M | 0.00 | 79.71K | 237.55K | 172.68K | 250.00K | -1.50M | 100.00K | 7.30M | 0.00 | 200.00K |
| Income Before Tax | -19.99M | -21.11M | -14.27M | -10.12M | -15.38M | -13.42M | -15.49M | -27.80M | -44.79M | -19.78M | -12.32M | -17.28M | -7.63M | -1.71M | -3.72M | -7.32M | 0.00 | -4.13M | -1.39M | 0.00 | -9.60M | -6.06M | -5.30M | -5.00M | -9.50M | -7.20M | 0.00 | -6.30M | -3.50M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -54.07% | -3,612.89% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,098.00% | -1,195.96% | -1,326.94% | -1,250.00% | -1,900.00% | -1,440.00% | 0.00% | -6,300.00% | -3,500.00% |
| Income Tax Expense | -1.64M | -1.43M | -94.00K | -117.00K | -360.00K | -4.20M | -11.08M | -12.00M | 2.76M | -718.00K | -22.00K | -231.00K | 2.22M | 10.11K | 49.93K | -114.05K | -245.88K | -5.48K | 36.63K | 677.06K | -67.57K | -295.25K | 12.09M | 13.60M | 0.00 | -200.00K | 7.40M | 0.00 | 400.00K |
| Net Income | -18.35M | -19.69M | -14.17M | -10.00M | -15.02M | -13.37M | -15.17M | -27.26M | -43.74M | -19.78M | -12.32M | -17.07M | -8.15M | -1.71M | -3.73M | -7.21M | -9.89M | -4.10M | -1.36M | -8.62M | -9.48M | -5.76M | -17.38M | -18.60M | -9.50M | -7.00M | -7.40M | -6.30M | -3.90M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -54.07% | -3,619.60% | 0.00% | 0.00% | 0.00% | 0.00% | -86,175.82% | -1,084.45% | -1,137.68% | -4,352.97% | -4,650.00% | -1,900.00% | -1,400.00% | -7,400.00% | -6,300.00% | -3,900.00% |
| EPS | -28.49 | -32.11 | -1.16 | -5.26 | -9.14 | -21.45 | -42.70 | -101.17 | -189.68 | -111.78 | -94.40 | -171.19 | -102.93 | -26.75 | -61.26 | -122.12 | -196.76 | -442.24 | -982.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -28.48 | -32.11 | -1.16 | -5.26 | -9.14 | -21.45 | -42.70 | -101.17 | -189.68 | -111.78 | -94.40 | -171.19 | -102.93 | -26.75 | -61.26 | -122.12 | -196.76 | -442.24 | -982.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 644.00K | 613.09K | 12.19M | 1.90M | 1.64M | 623.24K | 355.33K | 269.40K | 230.58K | 176.98K | 130.48K | 99.70K | 79.17K | 63.98K | 60.91K | 59.00K | 50.28K | 9.27K | 1.38K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 644.28K | 613.09K | 12.19M | 1.90M | 1.64M | 623.24K | 355.33K | 269.40K | 230.58K | 176.98K | 130.48K | 99.70K | 79.17K | 63.98K | 60.91K | 59.00K | 50.28K | 9.27K | 1.38K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer
ROCKVILLE, Md., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the outcomes of a recent Type...
Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma
ROCKVILLE, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the European...
Theriva Biologics Announces Pricing of $2.5 Million Public Offering
ROCKVILLE, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX) (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the...
Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- Target of 92 evaluable patients (46 in each of the control and VCN-01 treatment arms) enrolled across 15 sites in Spain and the USA within 21 months –
Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program
Theriva Biologics and the Universitat Autònoma de Barcelona to receive a total of €2.28 Million to support the THERICEL project, a suspension cell platform for manufacturing viral-based therapies Theriva Biologics and the Universitat Autònoma de Barcelona to receive a total...
Theriva Biologics Announces Reverse Stock Split
ROCKVILLE, Md., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced today a reverse stock split of its issued and...
Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma
ROCKVILLE, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the U.S. Food and...
Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer
ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the U.S. Food and Drug...
Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference
ROCKVILLE, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Company's Management will provide a...
Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results
- Reported topline data from the investigator sponsored Phase 1 trial of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma; trial results were determined to be positive by the study Monitoring Committee-
Source: https://incomestatements.info
Category: Stock Reports